Actively Recruiting
Observational Study on Bulevirtide Treatment for Chronic Hepatitis D Assessing Safety, Effectiveness, and Biomarkers
Led by Karolinska University Hospital · Updated on 2023-09-29
400
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of the antiviral drug Bulevirtide BLV in patients with Chronic Hepatitis D CHD, a severe and rare form of hepatitis. This observational study follows patients receiving 2 mg BLV, with or without pegylated interferon alfa-2a PEG-IFNb1-2a andor nucleostide analogues NA, as part of their routine medical care. The study also explores biological markers in blood, saliva, fecal samples, and liver tissue, along with assessing quality of life outcomes. Patients receive 2 mg of Bulevirtide daily via subcutaneous injection, with some also receiving PEG-IFNb1-2a andor NA depending on their usual treatment plan. The study follows patients prospectively, collecting samples and data to understand treatment response and safety. The research aims to gather additional information beyond earlier small studies and ongoing phase 3 trials. Participants will be monitored regularly with tests measuring virus levels, liver function, and immune response at multiple time points including baseline, monthly, and up to a year after treatment ends. Researchers will track medication adherence, adverse events, changes in liver elasticity, and quality of life. The total observation period includes continuous follow-up to evaluate long-term treatment effects and safety under normal care conditions.
CONDITIONS
Brief Title
Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Chronic Hepatitis D Patients
Research Team
S
Soo Aleman, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here